Azafaros to Detail Phase 3 Drug at J.P. Morgan Conference

Edgen Stock·Jan 08 2026, 09:41

Share to

Share to

Copy link

Key Takeaways

Azafaros, a clinical-stage biotechnology company, will present its lead product, nizubaglustat, at the upcoming J.P. Morgan Healthcare Conference. The drug, which targets rare neurological disorders, is currently in two pivotal Phase 3 studies funded by a recent capital raise, with key data anticipated in 2027.

Conference Showcase: Azafaros is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, highlighting its lead therapeutic candidate.
Lead Drug Candidate: The presentation will focus on nizubaglustat, a potential treatment for rare neurological conditions including GM1/GM2 gangliosidoses and Niemann-Pick type C disease.
Clinical Funding: Two pivotal Phase 3 studies for nizubaglustat are underway, financed by a €132 million Series B round completed in the first half of 2025, with clinical data expected in 2027.

Azafaros to Present Clinical Path on January 15

Dutch biotechnology firm Azafaros announced on January 8, 2026, that it will present its lead drug candidate at J.P. Morgan’s 44th Annual Healthcare Conference. The company is scheduled to detail the progress of nizubaglustat on Thursday, January 15, at 9:30 am UTC-8. The presentation will focus on the drug's potential as a treatment for rare lysosomal storage disorders with severe neurological symptoms, a significant area of unmet medical need.

€132M Financing Backs Pivotal Nizubaglustat Trials

Azafaros is advancing nizubaglustat, an oral, brain-penetrant small molecule, through two pivotal Phase 3 studies. These trials, which are currently enrolling patients with GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC), are financially supported by a €132 million Series B round that the company closed in the first half of 2025. The company expects to release data from these crucial late-stage studies in 2027.

The drug's development program builds on positive results from its Phase 2 RAINBOW study. Nizubaglustat has already garnered significant regulatory attention, receiving multiple designations from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), including Orphan Drug, Rare Pediatric Disease, and Fast Track designations, signaling a potentially streamlined path to market if the Phase 3 trials prove successful.